Like Gilead, Ab­b­Vie gets its ten­ta­cles in­to pact with Ten­tar­ix

The oc­topi at Ten­tar­ix Bio­ther­a­peu­tics are cel­e­brat­ing this morn­ing.

Ab­b­Vie plans to pay $64 mil­lion up­front for two pro­grams out of the San Diego biotech’s so-called Ten­ta­cles plat­form, spread across one tar­get in on­col­o­gy and the oth­er in im­munol­o­gy, the drug de­vel­op­ers said Thurs­day. If the Chica­go-area Big Phar­ma wants to ful­ly ac­quire the pro­grams af­ter the bi­o­log­ic can­di­dates have been nom­i­nat­ed, it will dish out fur­ther pay­ments of undis­closed size.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER